Introduction {#Sec1}
============

Microglial cells originate from monocyte/macrophage precursors and are regarded as the major immunocompetent cell type of the nervous system, constituting about 10% of all cells in the brain. The immune response of the brain is spatially segregated from the peripheral immune response by the blood brain barrier and together with astroglial cells and infiltrating peripheral immune cells, is predominantly executed by microglial cells. Thus, this cell type is rapidly activated in response to pathological signals such as ischemia or bacterial endotoxin and respond with morphological changes transforming the resting ramified microglia to an amoeboid form with phagocytic activity, proliferation and the production of a wide array of inflammatory mediators. Although microglial activation is a highly complex process, consisting of a number of interrelated extra- and intracellular pathways, it is a rather uniform response, which is triggered by any environmental challenge, which affects the functional integrity of the nervous tissue. Therefore, microglial activation is heavily implicated in the pathogenesis of virtually all CNS diseases and the following repair process, including brain and spinal cord injury, stroke, Alzheimer's (AD) and Parkinson's disease (PD), sclerosis multiplex (SM), amyotrophic lateral sclerosis (ALS) and sensory neuropathies. Apart from cytokines, growth factors, and other bioactive substances, purines are one of the most important mediators which regulate and orchestrate various aspects of microglial activation by the interaction of numerous subtypes of adenosine (P1) and nucleotide (P2) receptors.

Purine bioavailability under conditions leading to microglial activation {#Sec2}
========================================================================

The participation of purines in the microglial response presumes their accumulation in the extracellular space upon signals activating microglia. Extracellular purine availability in the nervous system is basically determined by the balance of release, and removal by enzymatic degradation and uptake. Whereas ATP is released per se, adenosine is thought to be generated in the extracellular space as a breakdown product of released ATP, but it could be also released on its own right, depending on the type of stimulus. Since ATP is ubiquitous, all metabolically active cells of the nervous system are able to synthesize ATP, which provides a potential pool for release. Therefore, the cellular source of released purines participating in microglial activation could be any cell type located in contact with microglia, i.e., nerve terminals, astrocytes, endothelial tissue and finally the microglial cells themselves as well. The majority of ATP is formed in the mitochondria by oxidative phosphorylation, which results in approximately 10 m[M]{.smallcaps} ATP concentration in the cytoplasm under normal metabolic conditions. In addition, ATP is also taken up and stored in synaptic vesicles of nerve terminals \[[@CR1]\] and astrocytes \[[@CR2]\]. On the other hand, the basal intracellular adenosine concentration is much less, in the low micromolar to high nanomolar range, and the majority of adenosine, which is taken up into cells is rapidly reincorporated into ATP stores, or deaminated by adenosine deaminase under normal metabolic conditions \[[@CR3]\].

A wide variety of stimuli are known to release ATP and/or adenosine to the extracellular space, which theoretically could lead to purine levels sufficiently high to activate nucleotide receptors expressed on the surface of microglia (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR1], [@CR3], [@CR4]\]. Although the stimulation-dependent release of ATP and adenosine upon conventional \[[@CR5], [@CR6]\] and high frequency \[[@CR7]\] neuronal activity is well documented, these stimuli probably result in a spatially restricted, localized increase in extracellular purine levels, which serve the synaptic transmission and the modulation of pre- and postsynaptic functions within the synaptic cleft. ATP-metabolizing ectoenzymes, present on the nerve terminal membrane, but also on the surface of microglia \[[@CR8]\], such as ectoNTPDases, the CD73/ecto-5--nucleotidase \[[@CR9]\] and nucleoside transporters may strongly limit purine availability under these conditions. On the other hand, pathological events such as mechanical or metabolic stress, inflammation, cellular injury or changes in the ionic environment are known also to powerfully stimulate purine release. This might result in a purine-rich extracellular milieu leading to a more widespread activation of receptors reaching also the neighboring or distant cells such as astrocytes and microglia as well. These signals include mechanical \[[@CR2], [@CR10], [@CR11]\] and hypotonic \[[@CR12]\] stimuli, hypoxia/hypoglycemia/ischemia and consequent energy deprivation \[[@CR13]--[@CR17]\], inflammatory signals, such as bacterial lypopolisaccharide (LPS) \[[@CR18], [@CR19]\], concanavalin-A \[[@CR20]\], or interleukin-1β (IL--β) \[[@CR21]\], and cytolysis, which could release purines not only from neurons but also from non-neuronal cells, i.e., from astrocytes, endothelial cells and from the microglia itself. Moreover, nucleotides and nucleosides by themselves may promote further release of purines, by a homo- or heteroexchange mechanism, if they reach relatively high concentration in the extracellular space \[[@CR22]\]. Figure 1A summary of purinergic pathways involved in microglial response. Since ATP is ubiquitous, it is present in the cytoplasm of nerve terminals, astrocytes, and the microglia itself. It is released to the extracellular space in response to a wide variety of signals, including neuronal firing, mechanical stimuli, ischemia/energy deprivation, bacterial endotoxin and cellular damage. Adenosine could be either released from cells, or generated from extracellular ATP via breakdown by NTPDase (*NTPD*) and CD73/5--nucleotidase (*CD73*) enzymes. The action of adenosine is terminated by its uptake into nerve terminals by the equilibrative nucleoside transporter system (*ENT*), and the same transporters could mediate the release of adenosine under energy deprivation. ATP acts on ionotropic P2X~7~ and P2X~4~ receptors, and also on metabotopic P2Y receptors, whereas adenosine activates metabotropic A~1~, A~2A~ and A~3~ receptors, all present on the surface of activated microglia. Whilst the activation of P2X receptors triggers an inward cationic current and depolarizes the microglial membrane, the activation of P2Y receptors is coupled to the G protein-phospholipase C (*PLC*) signal transduction pathway, both resulting in the elevation of intracellular Ca^2+^. P2X receptors are involved in the expression, posttranslational processing and secretion of various factors shaping the microglial response i.e., IL--β, IL--, IL--8, TNF-α, reactive oxygen intermediates (*ROI*), plasminogen, 2-arachydonoyl glycerate (*2-AG*), and microglial response factor−? (*MRF-1*) and thereby contribute to both the proinflammatory and antiinflammatory aspects of microglial activation. In addition, P2X~7~ receptors eventually also mediate apoptosis by caspase 1 activation. The stimulation of P2Y receptors hyperpolarizes the microglia, via an outward K^+^ conductance and inhibits the production of proinflammatory mediators. Adenosine receptors regulate the proliferation/survival of microglia, COX-2 expression and subsequent secretion of PGF~2~, and the production of nerve growth factor (*NGF*). For more details and references, see text. For the sake of clarity, details of intracellular signal transduction and transcriptional changes are not illustrated

Since ATP is a highly polarized molecule, which cannot pass freely through the cell membrane, it is also of interest to identify the mechanism, whereby it could enter the extracellular space. These include (1) vesicular exocytosis, (2) carrier-mediated release, (3) release through channels and membrane pores, (4) cytolytic release. Vesicular exocytosis is a prototype mechanism for neurotransmitters to enter the extracellular space, which is expected to be a \[Ca^2+^\]~o~-dependent process. Indeed, \[Ca^2+^\]~o~-dependent ATP and adenosine release in response to neuronal stimulation appears in many areas of the central and peripheral nervous system (for further references see \[[@CR1], [@CR3], [@CR4]\]. Moreover, recent findings indicate that vesicular ATP release could be derived not only from nerve terminals but also from astrocytes \[[@CR2]\].Although specific transporters capable for the transmembrane movement of ATP are yet to be molecularly identified in the nervous system, ABC (ATP binding cassette) proteins have been implicated as ATP transporters \[[@CR12], [@CR23], [@CR24]\] in non-neuronal cells. These transporters are also expressed in glial cells \[[@CR25]\] and mediate ATP release upon hypoosmotic challenge \[[@CR26], [@CR27]\]. On the other hand, transmembrane transporters for adenosine and other nucleosides are widely expressed in the nervous system. Specific nucleoside transporters consist of two families: equilibrative transporters (ENT) and concentrative transporters (CNT); the former is driven by the concentration gradient, the latter is driven by the sodium gradient \[[@CR28], [@CR29]\]. ENT transporters could carry different nucleosides, including adenosine and inosine, but not nucleotides, across the cell membrane in both directions, and they are regarded as the dominant nucleoside transporters of the brain. Since the intracellular adenosine level under normal metabolic state is in the low micromolar range \[[@CR3]\], if the ENT transporter is loaded from the extracellular space by excess adenosine, it mediates adenosine uptake into the nerve terminals. When adenosine is taken up, intracellular adenosine eliminating mechanisms, the adenosine kinase and adenosine deaminase enzymes convert it to AMP and inosine, respectively, thereby maintaining the driving force of the carrier. However, the ENT transporter could also act in a reverse direction under certain circumstances, mediating the release of adenosine into the extracellular space. This could occur during energy deprivation or metabolic distress, when ATP stores are depleted and AMP is generated intracellularly. Cytosolic 5--nucleotidase, which has a relatively high K~m~ for AMP (1--4 μ[M]{.smallcaps}), becomes active under these conditions and accumulates adenosine intracellularly. This adenosine then flows out to the extracellular space in a transporter-mediated manner \[[@CR3], [@CR30]\].Channels and pores are also potential candidates to drive the transmembrane movement of ATP. Connexin hemichannels are gap junction proteins, and their main function is to mediate electrical signaling, but they are also able to release neuroactive substances such as glutamate and ATP \[[@CR31]\]. They have been recently identified to mediate ATP release from astrocytes and other non-neuronal cells in response to mechanical stress \[[@CR32]--[@CR35]\].Although it has only recently received direct experimental proof \[[@CR36]\], any kind of cellular injury is generally thought to result in high local ATP concentrations in the extracellular space. In this case the millimolar cytoplasmic ATP is expected to flow out to the extracellular space through the membrane damage.

Apart from release, the other major factor determining purine bioavailability is their removal from the extracellular space by enzymatic degradation and transporters. Several enzyme families are responsible for the extracellular degradation of ATP in the nervous system. The first step of the inactivation of ATP is mediated by the family of ectonucleoside triphosphate diphospho-hydrolases (E-NTPDases, EC 3.6.1.5, also known as ectoATPase or apyrase), which are able to hydrolyse ATP and ADP to AMP \[[@CR9]\]. These enzymes show widespread distribution in the brain \[[@CR37], [@CR38]\] and have low micromolar K~m~ for ATP and ADP giving rise to rapid and highly effective hydrolysis of ATP in almost all neuronal tissues. In addition to the E-NTPDase family, ATP could also be dephosphorylated by ecto-nucleotide pyrophosphatases (E-NPPs) and by alkaline phosphatases, both having broader substrate specificity, but also widespread tissue distribution \[[@CR9]\].

The next step of extracellular inactivation is the hydrolysis of AMP by the ecto-5--nucleotidase (EC 3.1.3.5) enzyme, which is the rate-limiting step giving rise to the formation of adenosine, which is a new extracellular signal, acting on its own receptors. Ecto-5--nucleotidase exhibits micromolar K~m~ for AMP and is feed-forwardly inhibited by ATP, which results in a delayed, 'burst-like--adenosine production \[[@CR30]\]. It is also widely present in the brain, and it is predominantly associated to glial cells \[[@CR39], [@CR40]\], although its expression has been also demonstrated in purified nerve terminals \[[@CR41], [@CR42]\]. Finally, adenosine, generated by the ecto-5--nucleotidase, or released on its own right, is then taken up to the nerve terminal by specific nucleoside transporters (see above) and rapidly reincorporated to ATP stores, or deaminated extra- or intracellularly by the adenosine deaminase enzyme.

Modulation of microglial activation by P2 receptors {#Sec3}
===================================================

It has been known for a considerable time that microglial cells respond with both ionotropic and metabotropic actions to ATP application \[[@CR43]--[@CR47]\]. Whereas the activation of ligand-gated P2X receptors produces depolarization and Ca^2+^ influx through the receptor-ion channel complex, the stimulation of the G protein coupled P2Y receptors elicits hyperpolarization via phospholipase C (PLC)- and IP~3~-mediated mobilization of Ca^2+^ from intracellular stores and subsequent opening of K^+^ channels (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR47]\]. Now it is confirmed that all members of the P2 receptor family are expressed on resting and activated microglial cells kept in culture at the mRNA and/or protein level \[[@CR48], [@CR49]\].

Among various subtypes of the ionotropic P2 receptors, the role of P2X~7~ receptors in the microglial response is especially well delineated. Within the P2X receptor family, the P2X~7~ receptor has a distinguished role for several reasons. First, this receptor seems to function only in homo-oligomeric form, and is activated by relatively high concentrations of ATP. Second, this receptor was also known previously as P2z receptor, the 'cell death receptor-- its prolonged activation elicits the opening of a transmembrane pore, permeable to large molecular weight molecules up to 800 Da, which finally leads to cellular death. Last but not least, in spite of being cloned originally from the rat brain, it was suggested that P2X~7~ receptors are expressed predominantly on antigen-presenting immune cells and epithelia, and function as immunomodulatory receptors \[[@CR50], [@CR51]\]. Supporting this concept, a wealth of data confirm that P2X~7~ receptors regulate many aspects of immune response in the periphery \[[@CR52]\], but this holds true for microglial activation as well \[[@CR53]\].

The presence of the 'pore-forming--ATP receptor on microglial cells has already been described before the molecular identification of P2X~7~ receptors \[[@CR54], [@CR55]\]. The expression of P2X~7~ receptor transcripts and of the corresponding protein have been confirmed later in both cultured microglial cells \[[@CR51], [@CR56], [@CR57]\] and in situ microglial cells activated following middle cerebral artery occlusion \[[@CR51]\].

Primary microglial cultures and immortalized microglial cell lines respond to ATP and 2--3--O-(4-benzoyl-benzoyl)adenosine 5--triphosphate (BzATP) application with an inward current \[[@CR54], [@CR58], [@CR59]\], membrane depolarization, a sustained increase in intracellular free Ca^2+^ \[[@CR55]\], the uptake of high molecular weight fluorescent dyes \[[@CR55], [@CR58]\], and the secretion of IL--β upon an LPS stimulus \[[@CR55], [@CR60], [@CR61]\], with a pharmacological profile resembling that of P2X~7~ receptors. The central role of P2X~7~ receptors, as co-stimulators of the posttranslational processing of IL--β in microglial cells upon LPS challenge has been repeatedly proven \[[@CR19], [@CR61], [@CR62]\]. The mechanism underlying ATP dependent IL--β maturation and release in this cell type involves an outwardly directed K^+^ conductance and the activation of interleukin-1 convertase enzyme (ICE, also known as caspase 1) responsible for the cleavage of pro-IL1β to the mature, 17-kDa form \[[@CR61]\]. This mechanism appears to participate not only in the exogenous but also in the endogenous activation of P2X~7~ receptors, since LPS releases ATP from microglial cells, and the P2X~7~ receptor selective antagonist oxiATP prevents the LPS-induced IL--β release \[[@CR19]\].

Interestingly, ADP and AMP also act as agonists of P2X~7~ receptors in microglial cells in terms of membrane currents and LPS induced IL--β secretion, but only after 'priming--of the cells by ATP challenge \[[@CR63]\]. The molecular mechanism underlying the priming effect of ATP could be a reversible conformational change leading to the modification of the agonist binding motif, or the gating properties of the P2X~7~ receptor, or its activity-dependent phosphorylation. This priming effect, on the other hand, does not extend to the pore-forming property of recombinant and microglial P2X~7~ receptors \[[@CR63]\].

In addition to IL--β, the synthesis and release of other cytokines, are also stimulated by P2X~7~ receptor activation in the microglia. Hence, ATP is a full stimulus (i.e., without the requirement of priming by LPS) to induce TNFα production via a Ca^2+^-dependent, extracellular signal regulated protein kinase (ERK)/JNK/p38 signaling pathway \[[@CR64], [@CR65]\], although P2 receptors other than P2X~7~ may also participate in ATP-induced ERK activation \[[@CR65]\]. On the other hand, involvement of P2X~7~ receptors in the regulation of the production of the antiinflammatory cytokine, interleukin-6 (IL--) is more controversial. Whereas Inoue et al. \[[@CR66], [@CR67]\] reported that ATP-induced IL-- production is not mediated by P2X~7~ receptors, a recent study found markedly elevated levels of IL-- in the inflamed hindpaw of P2X~7~^−/−^ mice \[[@CR68]\], implicating the participation of this receptor in shaping IL-- levels. Moreover, Rampe et al. \[[@CR69]\] reported that P2X~7~ receptors play a role in the distinct modulation of cytokine secretory pathways not only after LPS, but also upon amyloid beta peptide (Aβ) pre-activation. Whereas the production of IL--β, IL--α, TNFα and IL--8 was increased, that of IL--, the anti-inflammatory cytokine was attenuated under these conditions, implicating the involvement of P2X~7~ receptors in the pathogenesis of Alzheimer's disease \[[@CR69]\].

High concentrations of ATP induce inducible nitric oxide synthase (iNOS) mRNA expression and increase nitric oxide (NO) production from rat microglia \[[@CR70]\], an effect potentially mediated by P2X~7~ receptors. In contrast, ATP by itself does not induce iNOS expression, but enhances IFNγ-induced iNOS expression and subsequent NO production in the murine BV-2 microglial cell line through an ERK1/2 and tyrosine kinase mediated pathway \[[@CR56]\]. ATP and BzATP also promote the generation of reactive oxygen intermediates (ROI), in particular superoxide, by interacting with P2X~7~ receptors, in a way depending on extracellular Ca^2+^ and the p38 mitogen activated protein kinase (MAPK) pathway \[[@CR71]\]. The stimulation of P2X~7~ receptors elicits a pronounced increase in the secretion of the endocannabinoid, 2-arachydonoylglycerate (2-AG) in primary microglial cell cultures by the activation of diacylglycerol lipase and the simultaneous inhibition of monoacylycerol lipase, the enzyme responsible for endocannabinoid degradation \[[@CR72]\]. This mechanism is noteworthy, because endocannabinoids are also recognized as key regulators of microglial activation \[[@CR73]\]. Finally, activation of P2X~7~ receptors by low concentration of agonists stimulates the release of the neuroprotective mediator plasminogen from cultured microglia \[[@CR74]\]. Therefore, regulation of the production of putatively protective (plasminogen, TNFα, 2-AG) and harmful (IL--β, NO) mediators by P2X~7~ receptors appears to follow a highly time- and concentration-dependent pattern \[[@CR67]\].

In addition to its role to regulate the production of inflammatory mediators, the activation of P2X~7~ receptors elicits changes in microglia at the transcriptional level; it rapidly activates the transcription factor nuclear factor of activated T cells (NFAT) in a \[Ca^2+^\]~o~-dependent manner \[[@CR75]\] as well as causes the nuclear translocation of NF-κB via ROIs and caspase activation leading to the transcription of a subset of NF-κB target genes \[[@CR76]\]. The expression of other transcription factors is regulated time-dependently upon P2X~7~ receptor activation. While an acute exposition (10 min to 1 h) of microglial cells to ATP and BzATP upregulates the production of the inflammation related protein microglial response factor (MRF)-1 \[[@CR77]\], long-term (6 h) exposure suppresses its transcription and synthesis \[[@CR78]\]. Moreover, a conditioned medium from cerebellar granule cells undergoing apoptosis also upregulated MRF-1 release in a P2X~7~ receptor-mediated manner, indicating that this mechanism plays a role in the neuron-microglia cross-talk during microglial activation in response to apoptotic signals \[[@CR78]\].

According to its pore-forming property, the sustained activation of P2X~7~ receptors leads to cytolysis in an apoptotic fashion in the microglia \[[@CR57]\]. The P2X~7~ receptor-mediated apoptosis involves the activation of the proteolytic pathway of the caspase activation, which leads to nuclear DNA damage, but is not an absolute requirement for the membrane damage and cytolysis; i.e., if caspases are inhibited, cell death proceeds through the necrotic pathway \[[@CR79]\]. Nevertheless, the P2X~7~ receptor activated IL--β secretion and cell death, although both processes involve caspases and both are eliminated in P2X~7~^−/−^ mice, appear to be independent from each other \[[@CR62]\].

Finally, P2X~7~ receptor activation also plays an important role in Ca^2+^ signaling between astrocytes and microglial cells \[[@CR11]\]. Astrocyte populations coordinate their functions via Ca^2+^ waves, and the spread of the Ca^2+^ signal is implemented by two ways: an intercellular pathway mediated by gap junctions, and an extracellular pathway mediated by ATP and P2 receptors \[[@CR80]\]. Moreover, astrocytes communicate by calcium-mediated signaling not only with each other but also with neighboring cells, including neurons and microglia. Thus, astrocyte-derived ATP activates P2X~7~ receptors on microglial cells and elicits Ca^2+^ signals in the microglia, a process which eventually leads to cytolysis of this cell type \[[@CR11]\]. It is interesting to note that P2X~7~ receptor-activation in astrocytes usually does not lead to cytolysis, whilst the same effect might cause cellular death in microglia. The reason for the different resistance of astrocytes and microglia against the P2X~7~ receptor mediated cytolysis is unknown.

The widespread and profound effects of P2X~7~ receptor activation on different aspects of microglial activation implicates the role of these receptors in the pathology of CNS and PNS diseases and provokes their applicability as therapeutic targets. Indeed, rapidly emerging knowledge supports such a role, in particular the demonstration of (1) the activity-dependent expression of P2X~7~ receptors under pathological conditions, and (2) the protective role of P2X~7~ receptor ligands in animal disease models. The diseases, in which microglial P2X~7~ receptors may play either a harmful or protective function include neurodegenerative and neuroinflammatory diseases, such as ischemia-reperfusion and traumatic injury, Alzheimer's disease, sclerosis multiplex, neuro- and retinopathies. In fact, the upregulation of microglial P2X~7~ receptors has been observed in several pathological models, including in vivo ischemia \[[@CR81]\], a transgenic model of Alzheimer's disease \[[@CR71]\], as well as in human tissue samples obtained from patients suffering in proliferative vitreoretinopathy \[[@CR82]\], and sensory nerve injury \[[@CR68]\].

The first study showing an upregulation of P2X~7~ receptors in the brain was that of Collo et al. \[[@CR51]\], who found an increased immunostaining for P2X~7~ receptors in activated microglial cells of the zona penumbra in the middle cerebral artery occlusion (MCAO) model. The microglial upregulation of P2X~7~ receptors in response to oxygen deprivation has also been documented in the retinal microglia \[[@CR83]\]. However, the ischemia-induced upregulation of P2X~7~ receptors appears in different cell types in a temporally distinct manner. In a more recent study, an early (1 day after MCAO occlusion) upregulation of the P2X~7~ receptor protein was observed in microglial cells, and later (4-- days after MCAO occlusion), the receptor was also overexpressed in neurons and astrocytes of the periinfarct area in spontaneously hypertensive rats, as revealed by co-localization studies with neuronal, astroglial and microglial markers \[[@CR81]\]. P2X~7~ receptor overexpression is also associated with microglial cells in other pathological models; e.g., P2X~7~ receptor immunoreactivity appears to be upregulated around amyloid plaques in activated microglia and astrocytes in the Tg2576 transgenic mice having mutant amyloid precursor protein (APP) \[[@CR71]\].

Altogether, these data indicate that the expression of P2X~7~ receptors is strongly activity-dependent during pathological situations. Nonetheless, whether the change in their expression pattern and functional responsiveness is a simple adaptive change or plays a more active pathogenetic role, warrants further investigation. It is also a largely open question whether the final outcome of versatile actions mediated by microglial P2X~7~ receptors is protective or harmful. As an example, P2X~7~ receptor deficient mice show increased susceptibility to experimental autoimmune encephalomyelitis (EAE), an animal model of sclerosis multiplex \[[@CR84]\], which is potentially due to the decreased microglial secretion of the protective endocannabinoid 2-AG \[[@CR72]\]. On the other hand, chronic inflammatory and neuropathic pain is almost completely abolished in the same mice line, which is attributed partly to disrupted microglial production of the inflammatory cytokine IL--β \[[@CR68]\]. Here we have to mention than in addition to those present on the surface of microglial cells, P2X~7~ receptors on other cell types (i.e., on astroglia and neurons) may also contribute to disease pathology.

In addition to P2X~7~ receptors, other subtypes of the P2 receptor family, responding to lower concentration of ATP, are also involved in different aspects of microglial activation \[[@CR85]\]. Thus, microglial Ca^2+^ influx could be also initiated by lower agonist concentrations, effects, which are associated to a non-P2X~7~ ionotropic, probably P2X~4~ receptor activation, and there is also a metabotropic, P2Y receptor mediated response \[[@CR59], [@CR85]\]. The expression of P2X~4~ receptors is enhanced in the spinal cord microglia after peripheral nerve injury \[[@CR86], [@CR87]\], and this receptor and the subsequent activation of the p38 MAP kinase pathway, have been shown to be involved in the generation of inflammatory and neuropathic pain \[[@CR88], [@CR89]\].

Early studies showed that exposure of microglial cells to ATP leads to the accumulation of immediate early gene products, c-fos, c-jun, junB and TIS11, effects most likely mediated by P2Y receptor activation \[[@CR90]\]. P2Y~1~ receptors mediate the inhibition of the LPS induced IL-1β, and TNF-α production \[[@CR91]\]. The level of proinflammatory cytokines therefore seems to be differentially and oppositely regulated by ionotropic and metabotropic P2 receptors. The production of the anti-inflammatory cytokine IL-- upon LPS challenge is inhibited by P2Y receptors \[[@CR91]\], although the involvement of pertussin toxin insensitive P2Y receptors in the induction of IL-- production has also been reported \[[@CR66]\]. In addition, stimulation of a G~i~ protein coupled, P2Y~12~-like receptor induces membrane ruffling and chemotaxis in cultured primary microglia \[[@CR92]\]. Finally, a recent study showed that the activation of P2Y but not P2X receptors induces cyclooxigenase-2 (COX-2) expression in the human microglia \[[@CR93]\].

In contrast to the plethora of experimental data obtained in glial cells kept in culture, much less data have been accumulated on the role of glial P2 receptors in more integrated systems, where the cell architecture and extracellular environment are retained. Nonselective cationic membrane currents could be recorded from identified resting microglial cells in acute brain slices in response to ATP (1 m[M]{.smallcaps}) and BzATP (0.2 m[M]{.smallcaps}) application, which presumably reflects the activation of P2X~7~ receptors, although the underlying receptor subtype has not been identified pharmacologically \[[@CR94]\]. BzATP also activates microglial P2X~7~ receptors in the isolated rat inner retina, which leads to the permeabilization of this cell type \[[@CR95]\]. Moreover, intrastriatal administration of ATP promotes cell death in the striatum in vivo, which extends to both neurons, astrocytes and microglial cells, as confirmed by immunostaining by cell-type specific markers NeuN, glial fibrillary acidic protein (GFAP) and OX-42, respectively \[[@CR96]\]. However, this effect was mimicked by α,β-methylene-ATP and ATPγS, and antagonized by reactive blue 2, but not by pyridoxal-phosphate-6-azophenyl-2--4--disulphonic acid (PPADS), and therefore is mediated by an unidentified subtype of P2 receptors.

Modulation of microglial activation by adenosine receptors {#Sec4}
==========================================================

Although relatively limited data have been accumulated on the adenosinergic modulation, microglial cells undoubtedly express functional A~1~, A~2A~ and A~3~ but not A~2B~ adenosine receptors \[[@CR97]\], which regulate different aspects of the microglial response \[[@CR98]\].

The pivotal role of A~1~ adenosine receptors in neuroinflammation is underscored by a recent study showing that A~1~ receptor null mice develop a severe form of experimental autoimmune encephalomyelitis (EAE), which indicates that endogenous adenosine might have a protective role in the defense against this disease \[[@CR99]\]. The involvement of endogenous adenosine in the development of the disease is supported by the downregulation of A~1~ adenosine receptors in microglia of A~1~^+/+^ mice and by the beneficial effect of caffeine, which upregulates A~1~ receptors and reduces disease severity concomitantly \[[@CR99]\]. Although the identification of cellular effects underlying the protective action of endogenous adenosine awaits further investigation, these findings offer a novel opportunity for the treatment of sclerosis multiplex and other neuroinflammatory diseases.

Activation of A~2A~ adenosine receptors differentially regulates the transcription and the de novo synthesis of various subtypes of K^+^ channels, via cAMP- and PKC-mediated pathways in cultured rat microglial cells; whereas the expression of Kv1.3 type K^+^ channels are enhanced at both the mRNA and the protein level, only the mRNA but not the protein synthesis of ROMK1 channels seems to be regulated by A~2A~ receptors \[[@CR100]\]. This mechanism could participate in the transition of the microglia from the resting state to the activated form, in which the function of K^+^ channels seems to play a pivotal role \[[@CR47]\]. The A~2A~ receptor agonist CGS21680 also increases the mRNA expression of nerve growth factor (NGF) and promotes the release of the NGF protein \[[@CR101]\] as a well as upregulates COX-2 and induces subsequent PGE~2~ release in rat microglia again by interacting with A~2A~ receptors and downstream activation of the cAMP pathway \[[@CR97]\].

Selective stimulation of A~3~ adenosine receptors induces p38 and ERK1/2 phosphorylation in primary murine microglia and in the N13 microglial cell line \[[@CR102], [@CR103]\]. This effect is mediated by G~i~ protein coupling and the phosphatidylinositol-3--kinase (PI3K) \[[@CR103]\], and is absent in microglial cells derived from A~3~ receptor deficient transgenic mice \[[@CR102]\].

Adenosinergic stimulation also influences the proliferation/survival of microglial cells; however, the clear-cut identity of the underlying receptor subtype involved in these effects is still uncertain. Thus, early studies indicate that only the simultaneous activation of A~1~ and A~2A~ receptors could promote microglia proliferation, but this action can be prevented by the A~1~ selective antagonist DPCPX \[[@CR104]\]. On the other hand, the adenosine receptor agonist 2-chloroadenosine also induces apoptosis in rat microglial cells; however, the identity of the adenosine receptor responsible for this latter effect remains unknown \[[@CR105]\].

Conclusions {#Sec5}
===========

It is now increasingly clear that ATP is one of the key players of microglial activation, which regulates numerous elements of microglial response from membrane potential to long-lasting transcriptional changes and also affects cell survival. Nevertheless, there are a number of aspects which need further investigation. Despite of the wealth of data on ATP mediated signaling obtained in cultured microglia, the present knowledge is poorly extrapolated to in vivo and disease conditions. The pathways of endogenous activation of purine receptors during the microglial response also need to be better explored. Finally, the mechanisms underlying the protective action of adenosine in the process of microglial activation awaits further investigation. The progress along this line is essential for the therapeutic utilization of purinergic signaling system in neurodegenerative diseases.
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